24 completed, 3 terminated, 1 unknown. 15 Phase 2, 14 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 13, Terminated 2 |
| Phase 1 | 14 | Completed 11, Terminated 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Recombinant Interleukin-12: new trials by email Literature Review of Recombinant Interleukin-12 trials Research Report on Recombinant Interleukin-12
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12 - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2011-02-01 | 2016-10-24 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma recombinant interleukin-12, aldesleukin - Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2002-12-01 | 2013-04-09 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2002-09-01 | 2013-01-16 |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy PSA prostate cancer vaccine, recombinant interleukin-12 - Prostate Cancer | Phase 2 | Completed | University of Chicago | 13 | 2001-11-01 | 2014-03-07 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors trastuzumab, paclitaxel, recombinant interleukin-12 - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2001-11-01 | 2013-06-04 |
| Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma rituximab, recombinant interleukin-12, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 99 | 2001-10-01 | 2013-08-26 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2001-10-01 | 2013-06-05 |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer recombinant interleukin-12 - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2001-07-01 | 2013-01-23 |
| Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride - Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2001-01-01 | 2013-06-19 | |
| Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer aldesleukin, recombinant interleukin-12, sargramostim - Head and Neck Cancer | Not applicable | Completed | NYU Langone Health | 2000-06-01 | 2012-11-09 | |
| Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors recombinant interleukin-12, aldesleukin, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2000-03-01 | 2013-02-01 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma recombinant interferon alfa, recombinant interleukin-12 - Kidney Cancer, Melanoma (Skin) | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2000-03-01 | 2013-03-21 |
| Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer recombinant interleukin-12 - Breast Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 5 | 1999-12-01 | 2016-07-19 |
| Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma recombinant interleukin-12, rituximab - Lymphoma | Phase 1 | Completed | Mayo Clinic | 1999-10-01 | 2011-08-03 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
| Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma filgrastim, recombinant interleukin-12, etoposide - Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 1999-01-01 | 2013-02-08 |
| Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12 - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 48 | 1998-11-01 | 2014-05-22 |
| Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer recombinant interferon alfa, recombinant interleukin-12 - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 1998-08-01 | 2013-02-01 |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer recombinant interleukin-12 - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 1998-08-01 | 2013-02-07 |
Showing 20 of 28. Sign in to see all of them.
Melanoma (6) · Breast Neoplasms (5) · Carcinoma, Ovarian Epithelial (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Non-Hodgkin (4) · Stomach Neoplasms (4) · Anus Neoplasms (3) · Bile Duct Neoplasms (3) · Burkitt Lymphoma (3)
National Cancer Institute (NCI) (16) · Eastern Cooperative Oncology Group (2) · University of Chicago (2) · University of Southern California (2) · Alliance for Clinical Trials in Oncology (1) · Beth Israel Deaconess Medical Center (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NYU Langone Health (1)
United States (27)
William Carson (3) · Jeffrey S. Weber, MD, PhD (2) · Thomas F. Gajewski, MD, PhD (2) · Alain Rook (1) · Anas Younes (1) · Daniel F. Hayes, MD (1) · David Avigan, MD (1) · Jon Wigginton (1) · Lawrence D. Kaplan, MD (1) · Martha Q. Lacy, MD (1) · Michael Atkins (1) · Michael B. Atkins, MD (1) · Michael J. Robertson, MD (1) · Moni A. Kuriakose, MD (1) · Pallavi P. Kumar, MD (1)
PMID 10815886, PMID 11211153, PMID 11756154, PMID 14984966, PMID 17846226, PMID 19243818
N01CM17003 (2), U01CA076576 (2), U10CA031946 (2), N01CM00071 (1), P01CA081403 (1), P30CA014599 (1), P30CA016672 (1), R01CA089442 (1), U01CA069912 (1), U10CA025224 (1)